Table 3.
Mean Incremental Cost per QALY Ratio | Interquartile Range | |
---|---|---|
FQHC Perspective2 | ||
SF-12 QALY* | 33,217 | 18,744 – 39,298 |
QWB QALY | 35,762 | 20,336 – 44,299 |
Depression-free day .2 QALY | 29,428 | 21,588 – 36,740 |
Depression-free day .4 QALY | 14,714 | 10,794 – 18,370 |
National Perspective3 | ||
SF-12 QALY* | 25,728 | 14,684 – 30,045 |
QWB QALY | 28,017 | 16,044 – 34,418 |
Depression-free day .2 QALY | 23,158 | 16,418 – 29,326 |
Depression-free day .4 QALY | 11,579 | 8,209 – 14,663 |
Abbreviations: QALY, quality adjusted life year; FQHC, federally qualified health system; SF-12, Medical Outcomes Study Short Form 12-item; QWB, Quality of Well Being scale; Depression-free day .2 QALY, depression free day to QALY conversion using .2 to estimate change from fully symptomatic depression to depression free; Depression-free day .4 QALY, depression free day to QALY conversion using .4 to estimate change from fully symptomatic depression to depression free.
The final model for depression-free days included: intervention, barriers to treatment, perceived need for treatment, SF-12 physical health component score, SF-12 mental health component score, employment, family history of depression, SCL-20. The QALY and cost models were similar except the SCL-20 was replaced by the baseline QALY measure or baseline cost measure, respectively.
Cost estimates are based on Arkansas FQHC prospective payment system rates for CHC visits, Arkansas Blue Cross Blue Shield data for non-CHC outpatient visits, University HealthSystem Consortium (UHC) Southern Region per diem rates for ER and inpatient visits, estimated 340B Drug Pricing Program costs for medication, 40% T1 lines monthly charges.
Cost estimates are based on Lifelink Health Plans Claims Database for outpatient, ER, and inpatient visits, lowest average wholesale price from Red Book for medication, 40% T1 lines monthly charges
designates base case analysis